Ex­sci­en­tia ends can­cer study as it fo­cus­es on oth­er tri­als of AI-dri­ven drug can­di­dates

AI drug dis­cov­ery and de­vel­op­ment com­pa­ny Ex­sci­en­tia is stop­ping a sol­id tu­mor tri­al as it re­fo­cus­es its in­ter­nal pipeline amid plans to ink an­oth­er part­ner­ship deal “by the end of this year,” CEO An­drew Hop­kins told End­points News.

The Ox­ford, UK-based biotech will end a Phase Ib/IIa tri­al of its oral cap­sule EXS21546 in com­bi­na­tion with Bris­tol My­ers Squibb’s Op­di­vo, Ex­sci­en­tia said Tues­day morn­ing. The com­pa­ny said it will ex­plore po­ten­tial part­ner­ships for fol­low-up com­pounds it cre­at­ed for the A2A mech­a­nism, not­ing “it will be chal­leng­ing for ‘546 to reach a suit­able ther­a­peu­tic in­dex.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER